- Home » News and EventsPage 19
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Appoints Charles Lickfold as Chief Information Officer
Jun 2, 2020
Catalent today announced the appointment of Charles Lickfold as Senior Vice President, Chief Information Officer. Mr. Lickfold succeeds John McGill, who plans to retire in September 2020.
Catalent Announces Acquisition of Japanese Facility to Provide Local and Global Clinical Supply Solutions
May 21, 2020
Catalent announced a deal to acquire a clinical packaging facility in Minakuchi, located in the Shiga prefecture of Japan, from Teva-Takeda Pharmaceuticals, Nagoya Aichi, Japan.
Catalent to Present Assessment Methods and Design Approaches for T-Cell Manufacturing Challenges at ISCT 2020 Virtual
May 20, 2020
Catalent today announced that Jean-François Chaubard, Senior Director, Open Innovation at Catalent Cell & Gene Therapy, will be presenting at the ISCT 2020 Paris Virtual conference.
Triphase Accelerator and Catalent Announce Interim Results of a Dose Escalation Phase 1 Clinical Trial of TRPH-222 in Patients with Non-Hodgkin’s Lymphoma
May 18, 2020
Triphase Accelerator and Catalent today announced interim results for Triphase Accelerator’s multi-center, open-label, monotherapy study of TRPH-222 in heavily pre-treated patients with relapsed and/or refractory B-cell lymphoma.
Proactive Strategies to Avoid Supply Delays to be Presented by Catalent at Outsourcing in Clinical Trials Virtual Conference
May 14, 2020
Catalent today announced that it will present at the upcoming conference, ‘Outsourcing in Clinical Trials 2020 – A Virtual Experience’.
Catalent Signs Development Agreement with Ennaid Therapeutics on its COVID-19 Lead Program
May 13, 2020
Catalent today announced a collaboration with Ennaid Therapeutics to develop an oral, antiviral treatment targeted at COVID-19.
Catalent Partners with Humanigen to Support FDA-Approved Phase 3 Lenzilumab Study for COVID-19
May 7, 2020
Catalent today welcomed the news by Humanigen, Inc., that it has dosed the first COVID-19 patient in its previously announced Phase 3 study for lenzilumab.
Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine
May 4, 2020
Arcturus and Catalent today announced a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate, intended to protect against the SARS-CoV-2 coronavirus.
Catalent Announces Next Generation of Cell & Gene Therapy Leadership
Apr 30, 2020
Catalent today announced the appointment of Manja Boerman, Ph.D., to the role of President, Cell & Gene Therapy. In this new role, Dr. Boerman will lead all of Catalent’s cell & gene therapy businesses worldwide.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.